A Randomized, Double-blind, Valsartan 80 Mg-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Fimasartan (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Boryung Pharmaceutical
- 10 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Jun 2013 New trial record